噬菌体治疗肺炎克雷伯菌感染的研究进展

Review of bacteriophage therapy for Klebsiella pneumoniae infection

随着细菌的进化以及部分抗生素的滥用,耐药细菌的感染已成为21世纪主要的公共卫生挑战之一。其中,耐药肺炎克雷伯菌(Klebsiella pneumoniae)问题尤为突出。噬菌体在治疗耐药细菌感染引起的疾病方面展现出一定的潜力及独特优势,但目前噬菌体治疗尚缺乏统一的临床指导规范。虽然临床上有少数将噬菌体用于治疗肺炎克雷伯菌感染的成功案例,但多数情况下是采用噬菌体配合抗生素疗法,噬菌体在其中的作用仍不明确。本文综合评述国内外研究数据,回顾与噬菌体治疗肺炎克雷伯菌感染相关的数个重点问题,包括噬菌体的特性以及影响其疗效的因素,旨在为肺炎克雷伯菌和其他耐药细菌的噬菌体治疗提供参考。

With the evolution of bacteria and the overuse of certain antibiotics,drug-resistant bacterial infections have emerged as a major public health challenge in the 21st century.Klebsiella pneumoniae,in particular,has aroused wide concern due to its drug-resistant nature.Bacteriophages have demonstrated the potential and advantages in treating bacterial infections caused by drug-resistant strains,while there are no clinical guidelines for phage therapy.Notably,even though a few successful cases of bacteriophage therapy have been documented in the treatment of K.pneumoniae infections,bacteriophages are used in combination with antibiotics in most cases and the role bacteriophages play remains unclear.This article provides an overview of bacteriophage therapies for K.pneumoniae infections,including their characteristics and the factors influencing their efficacy.We compiled and analyzed data from available studies,with the intention of offering valuable insights for the application of bacteriophage therapy in combating K.pneumoniae and other drug-resistant bacteria.